Cambridge Major Laboratories hires VP of Science and Technology

Dr Prasad Raje joins the company with 15 years of industry experience

Cambridge Major Laboratories, a chemistry outsourcing supplier to the pharmaceutical and biotechnology industries, has appointed Prasad Raje as VP of Science and Technology.

Raje will take overall responsibility for the company's active pharmaceutical ingredient (API) development organisation. He will also play a key role in the identification and implementation of new technologies and services.

Raje has more than 15 years of pharmaceutical industry experience. Prior to joining CML, he was president of Smithers Pharma Services, a CRO with expertise in analytical services, pharmaceutical R&D, and agrochemicals.

Prior to this, he held many roles at AMRI, initially as section head of chemical development, rising to president and managing director of AMRI India. He started his career as a senior research scientist at Abbott Laboratories.

You may also like

Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
Ingredients

AAIPharma Charleston sterile manufacturing receives MHRA approval

<p>International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.</p>
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Subscribe now